Ning Yan1, Cong Liu1, Fang Tian1, Ling Wang2, Yimin Wang3, Zhaoying Yang1, Yan Jiao4, Miao He5. 1. Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China. 2. Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin 130022, China. 3. Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China. 4. Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China. 5. Department of Anesthesia, The Second Hospital of Jilin University, Changchun, Jilin 130022, China.
Abstract
BACKGROUND: ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied. METHODS: The Oncomine database and "ESurv" tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients' survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining. RESULTS: ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (AUC = 0.671). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients' samples compared with adjacent tissues by IHC. CONCLUSIONS: Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.
BACKGROUND: ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied. METHODS: The Oncomine database and "ESurv" tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients' survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining. RESULTS: ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (AUC = 0.671). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients' samples compared with adjacent tissues by IHC. CONCLUSIONS: Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.
Authors: Rima Tawk; Vassiki Sanogo; Vakaramoko Diaby; Hong Xiao; Alberto J Montero Journal: Breast Cancer Res Treat Date: 2015-04-19 Impact factor: 4.872
Authors: Logan C Walker; Louise Marquart; John F Pearson; George A R Wiggins; Tracy A O'Mara; Michael T Parsons; Daniel Barrowdale; Lesley McGuffog; Joe Dennis; Javier Benitez; Thomas P Slavin; Paolo Radice; Debra Frost; Andrew K Godwin; Alfons Meindl; Rita Katharina Schmutzler; Claudine Isaacs; Beth N Peshkin; Trinidad Caldes; Frans Bl Hogervorst; Conxi Lazaro; Anna Jakubowska; Marco Montagna; Xiaoqing Chen; Kenneth Offit; Peter J Hulick; Irene L Andrulis; Annika Lindblom; Robert L Nussbaum; Katherine L Nathanson; Georgia Chenevix-Trench; Antonis C Antoniou; Fergus J Couch; Amanda B Spurdle Journal: Eur J Hum Genet Date: 2017-02-01 Impact factor: 4.246